Literature DB >> 18317708

Graft-versus-host disease and immunosuppression.

Neena Kapoor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18317708     DOI： 10.1007/s12026-007-0026-y

Source DB:  PubMed          Journal:  Immunol Res        ISSN： 0257-277X            Impact factor:   2.829


× No keyword cloud information.
  24 in total

1.  Hydroxychloroquine for the treatment of chronic graft-versus-host disease.

Authors:  A L Gilman; K W Chan; A Mogul; C Morris; F D Goldman; M Boyer; E Cirenza; A Mazumder; E Gehan; R Cahill; S Frankel; K Schultz
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

2.  Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.

Authors:  D Przepiorka; T L Smith; J Folloder; I Khouri; N T Ueno; R Mehra; M Körbling; Y O Huh; S Giralt; J Gajewski; M Donato; K Cleary; D Claxton; I Braunschweig; K van Besien; B S Andersson; P Anderlini; R Champlin
Journal:  Blood       Date:  1999-08-15       Impact factor: 22.113

3.  Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.

Authors:  K M Sullivan; R P Witherspoon; R Storb; H J Deeg; S Dahlberg; J E Sanders; F R Appelbaum; K C Doney; P Weiden; C Anasetti
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

4.  Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Corey Cutler; N Lynn Henry; Colm Magee; Shuli Li; Haesook T Kim; Edwin Alyea; Vincent Ho; Stephanie J Lee; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

5.  Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

Authors:  Laura J Johnston; Janice Brown; Judith A Shizuru; Keith E Stockerl-Goldstein; Monic J Stuart; Karl G Blume; Robert S Negrin; Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2005-01       Impact factor: 5.742

6.  Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors.

Authors:  S M Davies; T E DeFor; P B McGlave; J S Miller; C M Verfaillie; J E Wagner; D J Weisdorf
Journal:  Am J Med       Date:  2001-04-01       Impact factor: 4.965

7.  Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission.

Authors:  Michael G Kiehl; Ludwig Kraut; Rainer Schwerdtfeger; Bernd Hertenstein; Mats Remberger; Nicolaus Kroeger; Mathias Stelljes; Martin Bornhaeuser; Hans Martin; Christoph Scheid; Arnold Ganser; Axel R Zander; Joachim Kienast; Gerhard Ehninger; Dieter Hoelzer; Volker Diehl; Axel A Fauser; Olle Ringden
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

8.  Duration of immunosuppressive treatment for chronic graft-versus-host disease.

Authors:  Betty L Stewart; Barry Storer; Jan Storek; H Joachim Deeg; Rainer Storb; John A Hansen; Frederick R Appelbaum; Paul A Carpenter; Jean E Sanders; Hans-Peter Kiem; Richard A Nash; Effie W Petersdorf; Carina Moravec; A James Morton; Claudio Anasetti; Mary E D Flowers; Paul J Martin
Journal:  Blood       Date:  2004-08-03       Impact factor: 22.113

9.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome.

Authors:  Neal Flomenberg; Lee Ann Baxter-Lowe; Dennis Confer; Marcelo Fernandez-Vina; Alexandra Filipovich; Mary Horowitz; Carolyn Hurley; Craig Kollman; Claudio Anasetti; Harriet Noreen; Ann Begovich; William Hildebrand; Effie Petersdorf; Barbara Schmeckpeper; Michelle Setterholm; Elizabeth Trachtenberg; Thomas Williams; Edmond Yunis; Daniel Weisdorf
Journal:  Blood       Date:  2004-06-10       Impact factor: 22.113
View more
  1 in total

1.  Severe Sepsis-Associated Morbidity and Mortality among Critically Ill Children with Cancer.

Authors:  Salim Aljabari; Alfred Balch; Gitte Y Larsen; Mark Fluchel; Jennifer K Workman
Journal:  J Pediatr Intensive Care       Date:  2018-12-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.